NEXTEVO, INC – Trademark Portfolio
Entity Type: 03
NEXTEVO, INC holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 5 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include NEXTEVO. The owner is based in CONSHOHOCKEN, PA.
181 WASHINGTON STREET
SUITE 450
CONSHOHOCKEN, PA 19428
Showing of trademarks Trademarks
Trademark Classifications
NEXTEVO, INC's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Advertising; business management; business administration; office functions
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Frequently Asked Questions
How many trademarks does NEXTEVO, INC have?
NEXTEVO, INC has 7 U.S. trademarks filed with the USPTO. Of these, 1 registered, 6 abandoned.
What trademark classes does NEXTEVO, INC file in?
NEXTEVO, INC files trademarks across 5 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 35 (Advertising & Business), Class 1 (Chemicals), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are NEXTEVO, INC's most well-known trademarks?
NEXTEVO, INC's registered trademark portfolio includes well-known marks such as NEXTEVO. These are among 1 currently registered trademark in the portfolio.
What is NEXTEVO, INC's trademark registration success rate?
NEXTEVO, INC has a 14% trademark registration rate, with 1 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.